New vaccine can beat Aids virus defences
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A RADICAL approach to developing an Aids vaccine has led to the creation of a successful antidote against the many different strains of the virus.
Scientists believe the results mark a significant breakthrough in the struggle to create a vaccine that works against all the sub-types of HIV known to be circulating.
More than 10 years of research into developing an Aids vaccine have been hampered by the virus's ability to change its outer coating and so evade the antibodies generated by inoculation.
One of the principal difficulties in developing an effective Aids vaccine is identifying a feature of HIV common to all strains of the virus. Scientists believe the latest research may now have done this.
A team of researchers from the University of Montana and New York University Medical Center managed to "freeze" an Aids virus in the act of contorting itself as it invaded a cell, exposing a part of its outer glycoprotein "envelope" of HIV not normally seen.
Having identified this hidden region, the scientists used it to generate a prototype vaccine they injected into mice to generate antibodies that would specifically attack it.
In a series of further experiments, published in the journal Science, they isolated these mouse antibodies and found that they successfully neutralised, or inhibited, 24 out of 25 strains of HIV isolated from patients.
Professor Jack Nunberg, of the University of Montana, said: "Our vaccine is the first which has elicited antibodies which can neutralise any virus from human patients. To see that the response is very broad offers real hope that a broadly effective HIV vaccine might be developed."
Dan Littman, professor of pathology at New York University, said the results are a "very encouraging development" in terms of developing a single vaccine to work against all strains of HIV.
"This is really the first example of being able to somehow trick the immune system into making broadly neutralising antibodies that are presumably active against the HIV envelope glycoprotein," Professor Littman said.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments